• News
    • Tech News
    • AI
  • Gadgets
    • Apple
    • iPhone
  • Gaming
    • Playstation
    • Xbox
  • Science
    • News
    • Space
  • Streaming
    • Netflix
  • Vehicles
    • Car News
  • Social Media
    • WhatsApp
    • YouTube
  • Advertise
  • Terms
  • Privacy & Cookies
  • LADbible Group
  • LADbible
  • UNILAD
  • SPORTbible
  • GAMINGbible
  • Tyla
  • FOODbible
  • License Our Content
  • About Us & Contact
  • Jobs
  • Latest
  • Topics A-Z
  • Authors
Facebook
Instagram
X
TikTok
Snapchat
WhatsApp
Submit Your Content
World Health Organization makes groundbreaking decision over Ozempic amid safety concerns

Home> Science> News

Published 17:10 1 May 2025 GMT+1

World Health Organization makes groundbreaking decision over Ozempic amid safety concerns

Skinny jabs are still all the rage

Tom Chapman

Tom Chapman

Featured Image Credit: UCG / Contributor via Getty
Health
Science
World News

Advert

Advert

Advert

As arguably the most-trusted health organization in the world, it tends to be the case that when the World Health Organization speaks out, we all listen. Now, the WHO has once again returned to the issue of Ozempic and other anti-diabetic medications by passing judgment on the so-called 'skinny jabs'.

Despite Ozempic's proposed usage as a treatment for type 2 diabetes, its ability to be used as an anti-obesity medicine and popularity among celebrity circles has seen it become the talk of the town. Big names like Kelly Osbourne, Oprah Winfrey, and even Elon Musk have admitted to taking GLP-1 jabs.

It's not only the rich and famous backing Ozempic, Wegovy, Mounjaro, and the rest, with a memo seen by Reuters claiming that the WHO is also jumping on the skinny jab bandwagon.

Advert

The WHO could be taking big steps in making GLP-1s available to more (UCG / Contributor / Getty)
The WHO could be taking big steps in making GLP-1s available to more (UCG / Contributor / Getty)

Although the WHO originally said it couldn't back these drugs due to a lack of data on their long-term effects, it's seemingly pulled a U-turn to suggest they'll be added to its essential medicines list.

If this is the case, the jabs would be more widely available around the globe. They're supposed to be prescribed by a medical professional, although there's been a rise in black market sales and people being easily get their hands on stockpiles without a referral.

As noted by Reuters, over a billion people around the world are now classed as obese, with around 70% of them living in low and middle-income countries that might not be able to afford the likes of Ozempic.

Advert

The United Nations has also called for a look into how access can be improved in these regions. With these medications coming in at over $1,000 a month, and some requiring permanent doses to keep the weight off, the WHO could look into bringing prices down.

Elon Musk is among the big names who've backed these drugs (Anna Moneymaker / Staff / Getty)
Elon Musk is among the big names who've backed these drugs (Anna Moneymaker / Staff / Getty)

Wegovy was developed by Novo Nordisk, while Zepbound is from Eli Lilly. Both mimic a hormone that slows digestion and helps us feel fuller for longer, with clinical trials showing how patients have been able to lose up to 20% of their body weight while on these drugs.

This conditional recommendation will supposedly be released in the WHO's new August guidelines on how to treat obesity, while separate guidelines are apparently in the works for children and adolescents.

Advert

In the meantime, experts are due to convene and decide whether GLP-1 drugs should be included in the WHO's essential medicines list. This is a catalog of drugs that should be readily available in all 'functioning' health systems, and make them more available in poorer countries. This previously happened with HIV drugs when they were included in 2002.

The memo notes that the patent for semaglutide, that's used in Wegovy, ends in 2026 for some territories, leading to a rush of companies trying to launch their own cheaper versions.

Even though the WHO might be heading toward backing GLP-1 drugs, it still raises concerns about pricing in LMICs (low- and middle-income countries): "The same mechanisms that are used in large-scale medicine access programmes may need to be adopted."

The WHO, Eli Lilly, and Novo Nordisk didn't respond to Reuters' request for comment.

  • US states report major spike in deadly 'valley fever' as World Health Organization issues frightening list
  • Study finds Ozempic may reverse signs of disease that contributes to 2,000,000 deaths per year
  • Doctors raise more concerns over stranded astronauts' health after even more delays arise
  • NASA responds to growing concerns over stranded astronaut's health following worrying new pictures

Choose your content:

4 hours ago
6 hours ago
8 hours ago
  • 4 hours ago

    World's biggest lithium reservoir with $1,500,000,000,000,000 worth of the precious metal hiding in supervolcano

    This could turn the US into a leading global supplier of the valuable metal

    Science
  • 4 hours ago

    Earth could be hit today by insane 600,000 mile-wide solar eruption that triggers extreme geomagnetic storm

    Scientists are warning that this could cause disruptions on Earth

    Science
  • 6 hours ago

    Scientists reveal people really can die from a broken heart but one gender is more like to suffer from it

    Heartbreak is now considered an actual health condition, and it can actually kill you

    Science
  • 8 hours ago

    Scientists build dystopian 32ft ‘black box’ solely designed to record the end of civilization

    It's the end of the world as we know it

    Science